Cisplatin pharmacokinetics in a patient with renal dysfunction

Area of Science:

• Pharmacokinetics
• Nephrology
• Oncology

Background:

• Cisdiamminedichloroplatinum (DDP), a platinum-based chemotherapy agent, is commonly used for cancer treatment.
• Acute renal failure can significantly alter drug metabolism and excretion, impacting patient outcomes.
• Hemodialysis is a crucial supportive therapy for patients with end-stage renal disease or acute kidney injury.

Observation:

• Platinum concentrations in plasma and urine were monitored during a three-day DDP therapy course in a patient with acute renal failure undergoing hemodialysis.
• Urine collections during the oliguric phase showed minimal DDP excretion (0.36-0.56% of the daily dose).
• Platinum was detectable in dialysate only within the first two hours post-DDP administration.

Findings:

• The plasma elimination half-life (t1/2beta) of platinum was markedly prolonged, approximately 240 hours, in the patient with severe renal impairment.
• This represents a threefold increase in the DDP elimination half-life compared to patients with normal renal function.
• Limited platinum clearance was observed via hemodialysis, primarily during the initial hours of treatment.

Implications:

• The prolonged platinum half-life in renal failure suggests a potential for increased toxicity and the need for dose adjustments.
• These findings highlight the importance of pharmacokinetic monitoring for platinum-based drugs in patients with compromised renal function.
• Further clinical studies are warranted to establish definitive dosing guidelines and manage potential adverse events associated with DDP in renally impaired patients.